CPI-006
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- CPI-006
- DrugBank Accession Number
- DB16488
- Background
CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal cancer). NCT04464395 and NCT04734873 assessed its use for hospitalized COVID-19 patients alone or with standard care.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- IMMUNOGLOBULIN G1 (302-GLUTAMINE), ANTI-(HUMAN 5'-NUCLEOTIDASE) (HUMAN-MUS MUSCULUS MONOCLONAL CPI-006 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS-MUSCULUS MONOCLONAL CPI-006 .KAPPA.-CHAIN, DIMER
- External IDs
- CPI-006
- CPX-006
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
CPI-006 is a humanized monoclonal antibody which binds to the CD73 cell-surface ectonucleotidase and causes activation of B cells and production of antibodies. It is an immunomodulatory compound currently being investigated against the SARS-CoV-2 virus.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 23ET6940RM
- CAS number
- 2451856-97-4
References
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) 1 somestatus stop reason just information to hide 1 Completed Treatment Bladder Cancer / Cervical Cancer / Colorectal Cancer / Endometrial Cancer / Metastatic Castration-Resistant Prostate Cancer (mCRPC) / Non-Hodgkin's Lymphoma (NHL) / Non-Small Cell Lung Cancer (NSCLC) / Ovarian Cancer / Pancreatic Cancer / Renal Cell Carcinoma (RCC) / Sarcomas / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Triple-Negative Breast Cancer 1 somestatus stop reason just information to hide 1 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at January 21, 2021 01:47 / Updated at July 19, 2024 10:02